PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.77%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-6.04%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-65.74%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-47.67%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-53.82%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
12.14%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
7.50%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
-13.29%
Negative OCF growth is a critical warning sign. Benjamin Graham would check if receivables are ballooning or if core sales are declining.
-13.04%
Negative FCF growth reveals potential liquidity pressures or large capex overshadowing cash generation. Benjamin Graham would demand deeper scrutiny.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24856.69%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
-19589.97%
A negative 5Y OCF/share CAGR indicates declining cash generation per share mid-term. Benjamin Graham would see this as a red flag unless explained by short-term strategic investments.
63.13%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
-19587.84%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
-19245.92%
A negative 5Y net income/share CAGR reveals a mid-term deterioration in bottom-line earnings. Benjamin Graham would be cautious unless a credible turnaround is visible.
62.10%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
30196.53%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
5954.03%
5Y equity/share CAGR above 12% – Strong mid-term book value expansion. Warren Buffett would see if steady profits and moderate payout ratios sustain this pace.
827.17%
3Y equity/share CAGR above 12% – Excellent recent net worth expansion. Warren Buffett would check consistent earnings retention or beneficial buybacks driving this growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Asset growth 5-10% – Reasonable. Peter Lynch compares with revenue growth to ensure utilization remains high.
-14.41%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
A big drop in R&D might boost near-term earnings but risk starving the pipeline. Benjamin Graham sees if the firm is refocusing or if future growth suffers.
28.86%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.